Toremifene

• Description :

  Toremifene (Z-Toremifene) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 μM and 2.6 μM, respectively[1][2].

• Product Name Alternative :

  Z-Toremifene; NK 622 (free base) ; FC-1157a (free base)

• UNSPSC :

  12352005

• Hazard Statement :

  H301, H311, H331, H341

• Target :

  Estrogen Receptor/ERR

• Type :

  Reference compound

• Related Pathways :

  Vitamin D Related/Nuclear Receptor

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer; Infection

• Assay Protocol :

  https://www.medchemexpress.com/toremifene.html

• Concentration :

  10mM

• Purity :

  99.86

• Solubility :

  DMSO : 62.5 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  ClCC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCN(C)C)C=C2)\C3=CC=CC=C3

• Molecular Formula :

  C26H28ClNO

• Molecular Weight :

  405.96

• Precautions :

  H301, H311, H331, H341

• References & Citations :

  [1]Matthew R Smith, Selective Estrogen Receptor Modulators to Prevent Treatment-Related Osteoporosis.Rev Urol. 2005; 7 (Suppl 3) : S30-S35.|[2]Gauri J Sabnis, Luciana Macedo, Olga Goloubeva, Toremifene - Atamestane; Alone or In Combination: Predictions from the Preclinical Intratumoral Aromatase Model. J Steroid Biochem Mol Biol. 2008 January; 108 (1-2) : 1-7.|[3]Taneja SS, Morton R, Barnette G, Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. J Clin Oncol. 2013 Feb 10;31 (5) :523-9.|[4]Laura Cooper, et al. Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. J Med Chem. 2020 Sep 4.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Citation 01 :

  BioRxiv. 2020 May.|J Pharm Biomed Anal. 2021 Feb 20:195:113870.|Patent. US11696914.|Res Sq. 2020 Dec 31:rs.3.rs-100914.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|J Med Chem. 2020 Oct 8;63 (19) :11085-11099.|Viruses. 2021 Jun 28;13 (7) :1255.

• CAS Number :

  [89778-26-7]